Will Exact Sciences stock go up?

Stock Price Forecast The 17 analysts offering 12-month price forecasts for Exact Sciences Corp have a median target of 95.00, with a high estimate of 160.00 and a low estimate of 50.00. The median estimate represents a +157.24% increase from the last price of 36.93.

Is Exact Sciences a good stock to buy now?

Exact Sciences has received a consensus rating of Buy. The company’s average rating score is 2.75, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.

Is EXAS overvalued?

Exact Sciences Corporation – Hold Valuation metrics show that Exact Sciences Corporation may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of EXAS, demonstrate its potential to underperform the market.

Is Exact Sciences profitable?

It posted a net loss of $596 million in 2021, or a net loss of $3.48 per share, compared with a net loss of $824 million, or a loss of $5.45 per share, in 2020.

Should I sell my Exact Sciences stock?

Out of 8 analysts, 3 (37.5%) are recommending EXAS as a Strong Buy, 3 (37.5%) are recommending EXAS as a Buy, 2 (25%) are recommending EXAS as a Hold, 0 (0%) are recommending EXAS as a Sell, and 0 (0%) are recommending EXAS as a Strong Sell. What is EXAS’s earnings growth forecast for 2022-2024?

Does exact sciences pay a dividend?

EXAS does not currently pay a dividend.

Should I sell EXAS?

Out of 8 analysts, 2 (25%) are recommending EXAS as a Strong Buy, 3 (37.5%) are recommending EXAS as a Buy, 3 (37.5%) are recommending EXAS as a Hold, 0 (0%) are recommending EXAS as a Sell, and 0 (0%) are recommending EXAS as a Strong Sell. What is EXAS’s earnings growth forecast for 2022-2024?

Is Exact Sciences a good company to work for?

Exact Sciences is #7 on Great Place to Work and Fortune’s list of the 2020 Best Workplaces in Health Care & Biopharma. The ranking is based on survey responses reflecting the nearly 800,000 employees working at Great Place to Work-Certified organizations in the Health Care & Biopharma industry.

What exact sciences sell?

Exact Sciences Corp. is a molecular diagnostics company specializing in the detection of early stage cancers. The company’s initial focus was on the early detection and prevention of colorectal cancer, in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer.

Should I buy EXAS?

What kind of company is Exact Sciences?

Description. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

What is Exact Sciences 401k match?

Exact Sciences matches 100% of contributions that you make into your 401(k) account up to 6% of salary. The company match is made once per year in company stock. It is important to review your allocation after this contribution is made each year so you do not become overly concentrated.

Who are Exact Sciences competitors?

Exact Sciences competitors include Denali Therapeutics and Halozyme Therapeutics. Exact Sciences ranks 1st in Gender Score on Comparably vs its competitors.

What does Exact Sciences sell?

Does Pfizer own Cologuard?

Pfizer quit on Cologuard a while ago In 2018, when Exact Sciences hired Pfizer to co-promote Cologuard, Pfizer was a very different company. Shortly after signing the agreement with Exact Sciences, Pfizer’s former CEO Ian Read handed the leadership role to Albert Bourla.

What kind of company is exact sciences?

How many employees does Exact Sciences have?

Exact Sciences is one of the world’s leading cancer diagnostics companies, with more than 4,000 employees engaged worldwide in the pursuit of earlier, smarter answers in the fight against cancer.

How do I contact cologuard?

Cologuard® colorectal cancer screening test is a registered trademark of Exact Sciences Corporation. To report any adverse effects from using this kit, or if you need assistance, please call us at 1-844-870-8870. We are available 24 hours a day, 7 days a week to answer your questions.

Who owns exact science?

Exact Sciences (company)

Innovation One, the headquarters of Exact Sciences in Madison, Wisconsin (2020).
Founders	Stanley Lapidus Anthony P. Shuber
Headquarters	Madison, Wisconsin, U.S.
Key people	Kevin Conroy (Chairman, President & CEO) Jorge Garces (Chief Science Officer)
Products	Cologuard, Oncotype DX, Oncotype MAP

Is that Katie Couric in the Cologuard commercial?

Exact Sciences enlists Katie Couric for new commercial to promote Cologuard, colorectal cancer screening.

What is the price target for Exact Sciences stock?

The average twelve-month price target for Exact Sciences is $140.38 with a high price target of $168.00 and a low price target of $95.00. Learn more Do Wall Street analysts like Exact Sciences more than its competitors? Analysts like Exact Sciences stock more than the stock of other Medical companies.

What is the upside from Exact Sciences (Exact) stock?

According to analysts, Exact Sciences’s stock has a predicted upside of 36.79% based on their 12-month price targets. What analysts cover Exact Sciences? Exact Sciences has been rated by BTIG Research, Cowen, Craig Hallum, Raymond James, Robert W. Baird, SVB Leerink, and Wells Fargo & Company in the past 90 days.

Is exact sciences efficiently growing its dividend?

Exact Sciences does not have a long track record of dividend growth. In the past three months, Exact Sciences insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,588,637.00 in company stock. Only 1.40% of the stock of Exact Sciences is held by insiders.

What is exact sciences'(EXAs) stock symbol?

What is Exact Sciences’ stock symbol? Exact Sciences trades on the NASDAQ under the ticker symbol “EXAS.” Who are Exact Sciences’ major shareholders? Exact Sciences’ stock is owned by a variety of institutional and retail investors.